Adia Nutrition Inc. Supports Heroes and Their Families with TRICARE In-Network Application, Advancing Regenerative Care Through Adia Med
Adia Nutrition Inc. (OTCQB: ADIA) has announced that its medical subsidiary, Adia Med, has filed to become an in-network provider with TRICARE, a healthcare program serving 9.5 million military-related beneficiaries. The company expects to secure TRICARE provider status by August 31, 2025, accessing a program that disbursed $50.6 billion in medical treatments in FY2019.
Additionally, Adia Med anticipates approval as a United Healthcare provider by August 1, 2025, and has begun submitting its first patient insurance claims. The company offers regenerative treatments including Umbilical Cord Blood Stem Cell therapies, Autologous Hematopoietic Stem Cell Transplantation, and Therapeutic Plasma Exchange at its Winter Park clinic.
Adia Nutrition Inc. (OTCQB: ADIA) ha annunciato che la sua controllata medica, Adia Med, ha presentato la domanda per diventare un fornitore in rete di TRICARE, un programma sanitario che serve 9,5 milioni di beneficiari legati al mondo militare. L'azienda prevede di ottenere lo status di fornitore TRICARE entro il 31 agosto 2025, accedendo a un programma che ha erogato 50,6 miliardi di dollari in trattamenti medici nell'anno fiscale 2019.
Inoltre, Adia Med si aspetta di ricevere l'approvazione come fornitore United Healthcare entro il 1° agosto 2025 e ha già iniziato a inviare le prime richieste di rimborso assicurativo per i pazienti. La società offre trattamenti rigenerativi, tra cui terapie con cellule staminali del sangue del cordone ombelicale, trapianto autologo di cellule staminali ematopoietiche e scambio plasmatico terapeutico presso la sua clinica di Winter Park.
Adia Nutrition Inc. (OTCQB: ADIA) ha anunciado que su filial médica, Adia Med, ha solicitado convertirse en un proveedor dentro de la red de TRICARE, un programa de salud que atiende a 9.5 millones de beneficiarios relacionados con el ámbito militar. La compañía espera obtener el estatus de proveedor TRICARE para el 31 de agosto de 2025, accediendo a un programa que distribuyó 50.6 mil millones de dólares en tratamientos médicos en el año fiscal 2019.
Además, Adia Med anticipa la aprobación como proveedor de United Healthcare para el 1 de agosto de 2025 y ya ha comenzado a presentar sus primeras reclamaciones de seguros para pacientes. La empresa ofrece tratamientos regenerativos que incluyen terapias con células madre de sangre del cordón umbilical, trasplante autólogo de células madre hematopoyéticas e intercambio plasmático terapéutico en su clínica de Winter Park.
Adia Nutrition Inc. (OTCQB: ADIA)는 자회사인 Adia Med가 군 관련 수혜자 950만 명을 대상으로 하는 의료 프로그램인 TRICARE의 네트워크 내 제공자로 등록 신청을 했다고 발표했습니다. 회사는 2025년 8월 31일까지 TRICARE 제공자 자격을 확보할 것으로 예상하며, 2019 회계연도에 506억 달러의 의료비를 지출한 프로그램에 접근할 수 있게 됩니다.
또한 Adia Med는 2025년 8월 1일까지 United Healthcare 제공자로 승인받을 것으로 예상하며, 첫 환자 보험 청구를 제출하기 시작했습니다. 회사는 윈터 파크 클리닉에서 제대혈 줄기세포 치료, 자가 조혈모세포 이식, 치료적 혈장 교환 등 재생 치료를 제공합니다.
Adia Nutrition Inc. (OTCQB : ADIA) a annoncé que sa filiale médicale, Adia Med, a déposé une demande pour devenir un prestataire en réseau auprès de TRICARE, un programme de santé couvrant 9,5 millions de bénéficiaires liés au milieu militaire. La société prévoit d'obtenir le statut de prestataire TRICARE d'ici le 31 août 2025, accédant ainsi à un programme qui a distribué 50,6 milliards de dollars en traitements médicaux lors de l'exercice 2019.
De plus, Adia Med anticipe une approbation en tant que prestataire United Healthcare d'ici le 1er août 2025 et a commencé à soumettre ses premières demandes de remboursement d'assurance pour les patients. La société propose des traitements régénératifs, notamment des thérapies par cellules souches du sang de cordon ombilical, des transplantations autologues de cellules souches hématopoïétiques et des échanges plasmatiques thérapeutiques dans sa clinique de Winter Park.
Adia Nutrition Inc. (OTCQB: ADIA) hat bekannt gegeben, dass seine medizinische Tochtergesellschaft Adia Med einen Antrag gestellt hat, um ein Netzwerkanbieter bei TRICARE zu werden, einem Gesundheitsprogramm, das 9,5 Millionen militärbezogene Begünstigte betreut. Das Unternehmen erwartet, den TRICARE-Anbieterstatus bis zum 31. August 2025 zu erhalten und damit Zugang zu einem Programm, das im Geschäftsjahr 2019 medizinische Leistungen in Höhe von 50,6 Milliarden US-Dollar ausgezahlt hat.
Darüber hinaus rechnet Adia Med mit der Zulassung als United Healthcare-Anbieter bis zum 1. August 2025 und hat bereits begonnen, die ersten Versicherungsansprüche für Patienten einzureichen. Das Unternehmen bietet regenerative Behandlungen an, darunter Nabelschnurblutstammzelltherapien, autologe hämatopoetische Stammzelltransplantationen und therapeutischen Plasmataustausch in seiner Klinik in Winter Park.
- Potential access to TRICARE's 9.5 million beneficiaries network
- Expected approval as United Healthcare provider by August 1, 2025
- Access to TRICARE's substantial $50.6 billion medical treatment program
- Insurance reimbursement capability through both networks will improve treatment accessibility
- TRICARE and United Healthcare approvals still pending, not guaranteed
- Limited current clinic locations may restrict initial service reach
Winter Park, Florida--(Newsfile Corp. - July 23, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded leader in regenerative medicine and personalized wellness solutions, is thrilled to announce that its medical subsidiary, Adia Med, has officially filed to become an in-network provider with TRICARE, the healthcare program serving approximately 9.5 million active-duty service members, retirees, National Guard and Reserve members, and their families worldwide. This step, paired with Adia Med's anticipated approval as a United Healthcare provider by August 1, 2025, positions the company to transform healthcare access for millions. Adia Med expects to secure TRICARE in-network provider status by August 31, 2025, tapping into a program that paid out
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/259694_tricare-logo-9.jpg
This strategic filing positions Adia Med to serve TRICARE's extensive network of beneficiaries, including military personnel and their families, by offering innovative regenerative treatments such as Umbilical Cord Blood Stem Cell (UCB-SC) therapies, Autologous Hematopoietic Stem Cell Transplantation (AHSCT), and Therapeutic Plasma Exchange (TPE). These therapies, provided at Adia Med's Winter Park clinic and planned satellite locations, target conditions like Multiple Sclerosis, joint pain, torn tendons, and other orthopedic and wellness needs, aligning with Adia Nutrition's mission to revolutionize healthcare accessibility.
"We're fired up to support the 9.5 million TRICARE beneficiaries, including our nation's military heroes and their families, by bringing our regenerative therapies into their reach," said Larry Powalisz, CEO of Adia Nutrition Inc. "With TRICARE's massive
The TRICARE filing complements Adia Med's recent progress with United Healthcare, where the company has already begun submitting its first patient insurance claims, signaling near-final integration. By securing in-network status with both TRICARE and United Healthcare, Adia Med will join an elite group of providers meeting rigorous standards for clinical excellence, compliance, and patient care. These partnerships will enable insurance reimbursement for Adia Med, enhancing affordability and accessibility for patients seeking innovative treatments.
For questions, inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259694
FAQ
When will Adia Med (OTCQB: ADIA) become a TRICARE in-network provider?
What treatments does Adia Med offer for TRICARE beneficiaries?
How many beneficiaries will Adia Med reach through the TRICARE network?
What is the status of Adia Med's United Healthcare provider approval?
Where are Adia Med's treatment facilities located?
